No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NIVFWNewGenIvf Group Limited | 19.81K | 0.02 | -0.00 | 5.78% | -16.52% | -59.53% | ||
| NIVFNewGenIvf Group Limited | 677.01K | 0.51 | -0.02 | 5.78% | -16.52% | -59.53% |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Revenue | 4.12M | 5.94M | 5.14M | 5.43M |
| Revenue Growth % | - | 0.44% | -0.14% | 0.06% |
| Medical Costs & Claims | 3.09M | 4.41M | 3.45M | 3.61M |
| Medical Cost Ratio % | - | - | - | - |
| Gross Profit | 1.02M | 1.54M | 1.68M | 1.83M |
| Gross Margin % | - | - | - | - |
| Gross Profit Growth % | - | 0.5% | 0.09% | 0.09% |
| Operating Expenses | 826.02K | 1.14M | 1.64M | 2.8M |
| OpEx / Revenue % | - | - | - | - |
| Depreciation & Amortization | 342.54K | 303.94K | 229.71K | 206.26K |
| Combined Ratio % | - | - | - | - |
| Operating Income | 198.76K | -504.91K | 42.24K | -1.16M |
| Operating Margin % | - | - | - | - |
| Operating Income Growth % | - | -3.54% | 1.08% | -28.46% |
| EBITDA | 541.3K | -200.96K | 271.95K | -953.74K |
| EBITDA Margin % | - | - | - | - |
| Interest Expense | 88.29K | 77.76K | 46.18K | 778.66K |
| Non-Operating Income | -45.72K | -23.04K | -112K | -978K |
| Pretax Income | 156.18K | 500.65K | 108.42K | -961K |
| Pretax Margin % | - | - | - | - |
| Income Tax | 294.72K | 208.14K | 0 | -487K |
| Effective Tax Rate % | - | - | - | - |
| Net Income | -533 | 458.67K | 130.19K | -525K |
| Net Margin % | - | - | - | - |
| Net Income Growth % | - | 861.54% | -0.72% | -5.03% |
| EPS (Diluted) | -0.01 | 64.60 | 12.85 | -23.05 |
| EPS Growth % | - | - | -0.8% | -2.79% |
| EPS (Basic) | -0.01 | 64.60 | 12.85 | -23.05 |
| Diluted Shares Outstanding | 50.74M | 193.69K | 253.73K | 569.25K |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Total Assets | 1.41M | 70.79M | 4.49M | 3.58M |
| Asset Growth % | - | 49.1% | -0.94% | -0.2% |
| Total Investment Assets | 0 | 70.69M | 21.27M | 204K |
| Long-Term Investments | 0 | 70.69M | 21.26M | 204K |
| Short-Term Investments | 0 | 0 | 0 | 0 |
| Total Current Assets | 820.39K | 91.73K | 2.46M | 3.17M |
| Cash & Equivalents | 28.76K | 54.72K | 54.1K | 457.74K |
| Receivables | 750.35K | 1000K | 519.55K | 1000K |
| Other Current Assets | 0 | -2.33M | 373.68K | 73.92K |
| Goodwill & Intangibles | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| PP&E (Net) | 592.38K | 506.34K | 446K | 371.67K |
| Other Assets | 0 | -506.34K | -19.67M | 33.33K |
| Total Liabilities | 2.33M | 2.46M | 1.24M | 5.06M |
| Total Debt | 925.97K | 452.04K | 332.55K | 3.03M |
| Net Debt | 897.2K | 397.32K | 278.45K | 2.57M |
| Long-Term Debt | 0 | 0 | 0 | 2.33M |
| Short-Term Debt | 512.82K | 0 | 213.57K | 582.45K |
| Total Current Liabilities | 2.07M | 50K | 1.12M | 2.72M |
| Accounts Payable | 46.93K | 104.65K | 172.63K | 1.3M |
| Deferred Revenue | 812.16K | 1.36M | 7.94K | 63.49K |
| Other Current Liabilities | 0 | -2.51M | -15.59K | 554.38K |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Liabilities | 0 | 2.17M | 0 | 0 |
| Total Equity | -914.91K | 67.86M | 3.25M | -1.48M |
| Equity Growth % | - | 75.17% | -0.95% | -1.46% |
| Shareholders Equity | -775.94K | 68.32M | 3.74M | -1.05M |
| Minority Interest | -138.97K | -462.43K | -490.05K | -433.14K |
| Retained Earnings | -1.05M | -591.54K | -461.35K | -985.99K |
| Common Stock | 5.6K | 67.34M | 21.27M | 0 |
| Accumulated OCI | 10.85K | 9.57K | -7.29K | 18.88K |
| Return on Equity (ROE) | - | 0.01% | 0% | -0.6% |
| Return on Assets (ROA) | -0% | 0.01% | 0% | -0.13% |
| Equity / Assets | - | - | - | - |
| Debt / Equity | - | 0.01x | 0.10x | - |
| Book Value per Share | -0.02 | 350.35 | 12.79 | -2.60 |
| Tangible BV per Share | - | - | - | - |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Cash from Operations | 1.43M | -527.12K | -1.79M | -8.26M |
| Operating CF Growth % | - | -1.37% | -2.4% | -3.61% |
| Operating CF / Revenue % | - | - | - | - |
| Net Income | -138.53K | 500.65K | 130.19K | -474.1K |
| Depreciation & Amortization | 342.54K | 303.94K | 229.71K | 206.26K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 208.14K | 0 | -486.71K |
| Other Non-Cash Items | 497.6K | -2.25M | -60.51K | 247.54K |
| Working Capital Changes | 731.39K | 710.35K | -2.09M | -7.76M |
| Cash from Investing | -16.57K | -69.69M | -69.85K | -53.05K |
| Capital Expenditures | -16.57K | -94.45K | -69.85K | -53.05K |
| Acquisitions | 0 | 0 | 0 | 0 |
| Purchase of Investments | 0 | -69.69M | -780K | 0 |
| Sale/Maturity of Investments | 0 | 0 | 0 | 0 |
| Other Investing | 0 | 94.45K | 780K | 0 |
| Cash from Financing | -1.54M | 70.27M | 1.91M | 8.68M |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 |
| Stock Issued | 0 | 71.87M | 192.31K | 0 |
| Debt Issuance (Net) | 495.6K | 108.73K | -9.32K | 1000K |
| Other Financing | -2.04M | -1.71M | 1.72M | 98.64K |
| Net Change in Cash | -77.43K | 54.72K | -615 | 403.64K |
| Exchange Rate Effect | 50.51K | 0 | -46.13K | 44.97K |
| Cash at Beginning | 106.19K | 28.76K | 54.72K | 54.1K |
| Cash at End | 28.76K | 54.72K | 42.22K | 457.74K |
| Free Cash Flow | 1.42M | -621.58K | -1.84M | -8.32M |
| FCF Growth % | - | -1.44% | -1.95% | -3.53% |
| FCF Margin % | - | - | - | - |
| FCF per Share | 0.03 | -3.21 | -7.24 | -14.61 |
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Combined Ratio | 95.17% | 93.29% | 99.18% | 117.93% |
| Medical Cost Ratio | 75.11% | 74.13% | 67.25% | 66.37% |
| Return on Equity (ROE) | - | 1.37% | 0.37% | -59.53% |
| Return on Assets (ROA) | -0.04% | 1.27% | 0.35% | -13.02% |
| Equity / Assets | -64.76% | 95.86% | 72.33% | -41.42% |
| Book Value / Share | -0.02 | 350.35 | 12.79 | -2.6 |
| Debt / Equity | - | 0.01x | 0.10x | - |
| Revenue Growth | - | 44.34% | -13.59% | 5.78% |
| 2023 | 2024 | |
|---|---|---|
| THAILAND | 1.36M | 2.18M |
| THAILAND Growth | - | 60.31% |
| CAMBODIA | 621.62K | 601.53K |
| CAMBODIA Growth | - | -3.23% |
| CHINA | - | 8.37K |
| CHINA Growth | - | - |
| HONG KONG | - | 3.08K |
| HONG KONG Growth | - | - |
NewGenIvf Group Limited (NIVF) grew revenue by 5.8% over the past year. This is steady growth.
NewGenIvf Group Limited (NIVF) reported a net loss of $0.5M for fiscal year 2024.
NewGenIvf Group Limited (NIVF) has a return on equity (ROE) of -59.5%. Negative ROE indicates the company is unprofitable.
NewGenIvf Group Limited (NIVF) has a combined ratio of 117.9%. A ratio above 100% means claims and expenses exceed premiums.